Format

Send to

Choose Destination
Mol Ther Methods Clin Dev. 2015 Feb 4;2:14065. doi: 10.1038/mtm.2014.65. eCollection 2015.

Inhalable delivery of AAV-based MRP4/ABCC4 silencing RNA prevents monocrotaline-induced pulmonary hypertension.

Author information

1
Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1166, ICAN , Paris, France ; INSERM, UMR_S 1166, ICAN , Paris, France.
2
Sorbonne Universités, UPMC Univ Paris 06, PECMV core , Paris, France.
3
Cardiovascular Research Center, Icahn School of Medicine , New York, New York, USA.
4
Bayer Healthcare, Global Drug Discovery , Wuppertal, Germany.
5
Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1166, ICAN , Paris, France ; INSERM, UMR_S 1166, ICAN , Paris, France ; AP-HP, Hôpital Pitié-Salpêtrière, Department of Pharmacology & Institute of CardioMetabolism and Nutrition , Paris, France.

Abstract

The ATP-binding cassette transporter MRP4 (encoded by ABCC4) regulates membrane cyclic nucleotides concentrations in arterial cells including smooth muscle cells. MRP4/ABCC4 deficient mice display a reduction in smooth muscle cells proliferation and a prevention of pulmonary hypertension in response to hypoxia. We aimed to study gene transfer of a MRP4/ABCC4 silencing RNA via intratracheal delivery of aerosolized adeno-associated virus 1 (AAV1.shMRP4 or AAV1.control) in a monocrotaline-induced model of pulmonary hypertension in rats. Gene transfer was performed at the time of monocrotaline administration and the effect on the development of pulmonary vascular remodeling was assessed 35 days later. AAV1.shMRP4 dose-dependently reduced right ventricular systolic pressure and hypertrophy with a significant reduction with the higher doses (i.e., >10(11) DRP/animal) as compared to AAV1.

CONTROL:

The higher dose of AAV1.shMRP4 was also associated with a significant reduction in distal pulmonary arteries remodeling. AAV1.shMRP4 was finally associated with a reduction in the expression of ANF, a marker of cardiac hypertrophy. Collectively, these results support a therapeutic potential for downregulation of MRP4 for the treatment of pulmonary artery hypertension.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center